Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

HMN-214

HMN-214
Contact us for more batch information
Select Batch
Purity:100%
Resource Download

HMN-214

Catalog No. T2438Cas No. 173529-46-9
HMN-214 (IVX-214) is a potent PLK1 inhibitor with an average IC50 of 0.12 μM.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Pack SizePrice/USDAvailabilityQuantity
1 mg$34In Stock
2 mg$48In Stock
5 mg$77In Stock
10 mg$126In Stock
25 mg$230In Stock
50 mg$369In Stock
100 mg$531In Stock
500 mg$1,180In Stock
1 mL x 10 mM (in DMSO)$84In Stock
Bulk & Custom
Add to Cart
Questions
View More

Related Compound Libraries of "HMN-214"

Product Introduction

Bioactivity
Description
HMN-214 (IVX-214) is a potent PLK1 inhibitor with an average IC50 of 0.12 μM.
In vitro
HMN-214, an oral prodrug of HMN-176, exhibits superior oral bioavailability. In nude mouse models carrying multi-drug resistant KB-A.1 cells, HMN-214 (10 mg/kg-20 mg/kg) significantly inhibits the expression of MDR1 mRNA. Additionally, in mouse xenograft models of PC-3, A549, and WiDr cells, HMN-214 (10 mg/kg-20 mg/kg) effectively suppresses tumor growth.
In vivo
HMN-214 is an orally administered prodrug that quickly converts to HMN-176, with limited in vitro data available. The active metabolite, HMN-176, demonstrates effective and broad-spectrum antitumor activity against a variety of cancer cell lines including HeLa, PC-3, DU-145, MIAPaCa-2, U937, MCF-7, A549, and WiDr, with an average IC50 value of 118 nM. HMN-176 at concentrations ranging from 250 nM to 2.5 μM inhibits mitotic spindle assembly and at 2.5 μM also impedes microtubule formation from the centrosome. These outcomes suggest that HMN-176's anticancer activity is, in part, mediated by disrupting centrosome-driven microtubule (MT) assembly during mitosis. Additionally, at 2.5 μM, HMN-176 delays the formation of the proper spindle assembly checkpoint in human RPE1 and CFPAC-1 cells. By disrupting the interaction between the NF-Y transcription factor and the MDR1 promoter, HMN-176 (3 μM) downregulates the expression of the multidrug resistance gene (MDR1). In HeLa cells, HMN-176 (3 μM) blocks cell cycle progression at the G2/M phase. HMN-176 also exhibits cytotoxic effects on both human and murine cell lines resistant to various treatments, including P388/CDDP, P388/VCR, K2/CDDP, and K2/VP-16, with IC50 values ranging from 143 nM to 265 nM.
Cell Research
Cells are seeded into a 96-well microplate at a density of 3 × 103–1 × 104 cells/well. Dilutions of HMN-214 or HMN-176 are added the next day and the plate is incubated for 72 hours. The inhibition of growth is measured by the MTT assay and IC50 values are then obtained.(Only for Reference)
AliasIVX-214, HMN214
Chemical Properties
Molecular Weight424.47
FormulaC22H20N2O5S
Cas No.173529-46-9
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year
Solubility Information
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
H2O: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 12 mg/mL (28.27 mM)
Solution Preparation Table
DMSO
1mg5mg10mg50mg
50 mM0.0471 mL0.2356 mL0.4712 mL2.3559 mL
100 mM0.0236 mL0.1178 mL0.2356 mL1.1779 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg,each TargetMol | Animal experiments animal weighs 20 g, and the dosage volume is 100 μL. A total of TargetMol | Animal experiments 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL.
Mother liquor preparation method: 2 mg of drug dissolved in 50 μLDMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μLDMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μLTween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.

Keywords